Publications by authors named "Hanren Dai"

Claim this Profile
M
Mucosal-Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets.
Cheng Zhu, Qian Huai, Yishan Du, Xingyu Li, Fumin Zhang, Ying Dai, Hanren Dai

MedComm (2020)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the role of GEM in systemic lupus erythematosus through multi-omics joint analysis.
Ruofei Chen, Xiao Zhang, Yifang Shang, Huaixuan Zhang, Xiaolei Li, Hanren Dai

Front Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of TREM2 in sepsis.
Jiejie Zhu, Tianyin Sun, Hanren Dai

J Clin Invest· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models.
Hanren Dai, Cheng Zhu, Qian Huai, Wentao Xu, Jiejie Zhu

J Hepatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages.
Qian Huai, Cheng Zhu, Xu Zhang, Hanren Dai, Xiaolei Li

Hepatol Commun· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Identification of Gamma-Glutamyl Hydrolase in Uterine Corpus Endometrial Carcinoma: a Predictive Model and Machine Learning.
Cheng Zhu, Yishan Du, Qian Huai, Nana Fang, Wentao Xu, Hanren Dai, Ying Dai

Reprod Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GDF15 Ameliorates Liver Fibrosis by Metabolic Reprogramming of Macrophages to Acquire Anti-Inflammatory Properties.
Xiaolei Li, Qian Huai, Cheng Zhu, Xu Zhang, Wentao Xu, Hanren Dai

Cell Mol Gastroenterol Hepatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesenchymal stromal/stem cells and their extracellular vesicles in liver diseases: insights on their immunomodulatory roles and clinical applications.
Qian Huai, Cheng Zhu, Xu Zhang, Hanren Dai, Xiaolei Li

Cell Biosci· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of immune-related cell-based machine learning for disease progression and prognosis of alcoholic liver disease.
Xu Zhang, Xuezhe Feng, Qian Huai, Cheng Zhu, Yingyin Sun, Hanren Dai

Clin Transl Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
Cheng Zhu, Qian Huai, Xu Zhang, Hanren Dai, Xiaolei Li

Int J Biol Sci· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China.
Xiaolei Li, Hanren Dai, Yao Wang, Zhiqiang Wu, Hua Wang

Lancet Haematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer.
Cheng Zhu, Siya Wang, Yishan Du, Ying Dai, Qian Huai, Hanren Dai

BMC Gastroenterol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal model establishment of whole-process management data for CAR-T therapy in China-how should this be done?
Xiaolei Li, Hanren Dai, Xian Li, Ping Li, Wenbin Qian

Cell Mol Immunol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring innate immunity in cancer immunotherapy: opportunities and challenges.
Xiaolei Li, Hanren Dai, Hua Wang, Weidong Han

Cell Mol Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy.
Xiaolei Li, Hanren Dai, Hua Wang

Oncoimmunology· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.
Yao Wang, Chuan Tong, Hanren Dai, Zhiqiang Wu, Xiao Han

Nat Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial.
Hanren Dai, Chuan Tong, Daiwei Shi, Meixia Chen, Yelei Guo

Oncoimmunology· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
Yang Liu, Yelei Guo, Zhiqiang Wu, Kaichao Feng, Chuan Tong, Hanren Dai

Cytotherapy· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.
Chuan Tong, Yajing Zhang, Yang Liu, Xingyu Ji, Wenying Zhang, Hanren Dai

Blood· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo

J Hematol Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo

J Hematol Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix.
Wenlong Zhang, Ling Liu, HuiFang Su, Qin Liu, Jie Shen, Hanren Dai

Br J Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity.
Jianshu Wei, Can Luo, Yao Wang, Yelei Guo, Hanren Dai

J Immunother Cancer· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.
Hejin Jia, Zhenguang Wang, Yao Wang, Yang Liu, Hanren Dai

J Hematol Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restoration of CD3CD56 cell level improves skin lesions in severe psoriasis: A pilot clinical study of adoptive immunotherapy for patients with psoriasis using autologous cytokine-induced killer cells.
Hanren Dai, Yong Zhou, Chuan Tong, Yelei Guo, Fengxia Shi

Cytotherapy· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis